Aroa Biosurgery (ASX:ARX) Construction In Progress: A$6.95 Mil (As of Mar. 2026)


ASX:ARX Aroa Biosurgery Ltd ASX:ARX
62 GF Score
Price A$0.59
GF Value A$0.80
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Aroa Biosurgery Construction In Progress?

Aroa Biosurgery ASX:ARX +0.85% 62 Construction In Progress is A$6.95 Mil as of Mar. 2026. GuruFocus rates ASX:ARX with a GF Score™ of 62/100 and a GF Value™ of A$0.80 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Aroa Biosurgery's quarterly construction in progress declined from Mar. 2025 (A$7.64 Mil) to Sep. 2025 (A$0.00 Mil) but then increased from Sep. 2025 (A$0.00 Mil) to Mar. 2026 (A$6.95 Mil).

Aroa Biosurgery's annual construction in progress increased from Mar. 2024 (A$7.64 Mil) to Mar. 2025 (A$7.64 Mil) but then declined from Mar. 2025 (A$7.64 Mil) to Mar. 2026 (A$6.95 Mil).

Aroa Biosurgery Construction In Progress Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery Construction In Progress Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial 3.87 5.36 7.64 7.64 6.95

Aroa Biosurgery Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.64 0.00 7.64 0.00 6.95
ASX:ARX
62GF Score
Aroa Biosurgery Ltd ASX:ARX
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aroa Biosurgery Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of A$6.95 Mil mean?
Aroa Biosurgery (ASX:ARX) has a Construction In Progress of A$6.95 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Aroa Biosurgery and its competitors.
Is Aroa Biosurgery's Construction In Progress too high?
Aroa Biosurgery's current Construction In Progress is A$6.95 Mil. Overall, Aroa Biosurgery has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Construction In Progress compare to ABT and SYK?
Aroa Biosurgery's Construction In Progress of A$6.95 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Devices & Instruments company?
A good Construction In Progress depends on the Medical Devices & Instruments industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Aroa Biosurgery and its competitors. Aroa Biosurgery's current Construction In Progress is A$6.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.59 — trading 26.3% below its estimated fair value. The current Construction In Progress is A$6.95 Mil. Aroa Biosurgery's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Construction In Progress is A$6.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of A$0.59 is trading 26.3% below its estimated GF Value™ of A$0.80. GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.

Key valuation signals for ASX:ARX:

  • Construction In Progress: A$6.95 Mil
  • GF Value™: A$0.80 vs. price of A$0.59 (26.3% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aroa Biosurgery Business Description

Other Exchanges AROAF:USA
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
62GF Score

Get the complete analysis for ASX:ARX

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.59
Price
A$0.80
GF Value